Executive Summary / Key Takeaways

• Stereotaxis is undergoing a strategic transformation, shifting from a niche robotic system provider hampered by installation complexity and third-party catheter dependence to a potential platform player with easier-to-adopt technology and a proprietary catheter ecosystem.
• Recent financial results show early signs of this shift, with Q1 2025 revenue growing 9% year-over-year, driven by a significant 29% increase in recurring revenue from initial sales of acquired Map-iT catheters and the newly launched MAGiC ablation catheter in Europe.
• Key technological advancements like the construction-free GenesisX system (CE Mark obtained, US FDA submission pending) and proprietary catheters (MAGiC, MAGiC Sweep, EMAGIN) are designed to address historical limitations, improve the business model, and expand market reach beyond electrophysiology.
• Management guides for double-digit revenue growth in 2025, expecting recurring revenue to scale significantly throughout the year, reaching a $7 million quarterly run rate by Q4 2025, driven primarily by MAGiC adoption in Europe.
• While facing macroeconomic headwinds, supply chain risks, and intense competition from larger players like Medtronic (MDT), Abbott (ABT), and Boston Scientific (BSX), successful execution of the new product launches and strategic initiatives positions Stereotaxis for potential "breakout growth" in 2026 and beyond.

Stereotaxis, Inc. operates within the dynamic and growing medical robotics and interventional procedures market, primarily focused on electrophysiology (EP) and the treatment of cardiac arrhythmias. The company's core technology, Robotic Magnetic Navigation (RMN), represents a differentiated approach, using precise computer-controlled magnetic fields to guide flexible catheters and devices within the body. This method offers distinct advantages over manual techniques, including enhanced precision, stability, reach into complex anatomy, and potentially reduced patient harm and physician radiation exposure by allowing procedures from a shielded control cockpit. With over 150,000 patients treated globally and documented in over 500 clinical publications, the clinical value of RMN in complex EP cases is well-established.

Despite these foundational strengths and the multi-billion-dollar cardiac ablation market opportunity, Stereotaxis has historically faced significant structural impediments to broad adoption and profitable growth. Its prior generation systems required extensive and costly hospital construction for installation, leading to long, complex sales cycles. Crucially, the company relied on third-party catheters, notably from Johnson & Johnson (JNJ), for use with its robots. This dependence limited innovation, created supply chain vulnerabilities, and prevented Stereotaxis from capturing the significant recurring revenue stream associated with disposable catheter use in each procedure, effectively giving up the "razor blade" in a razor-razor blade business model.

Recognizing these limitations, Stereotaxis embarked on a comprehensive strategic transformation over the past decade. This strategy centers on developing an advanced product ecosystem designed to make robotic magnetic navigation more accessible, expand its clinical utility, and establish a robust, proprietary recurring revenue base. Key pillars include the development of a construction-free robotic system, a portfolio of proprietary robotically-navigated catheters, expansion into new endovascular indications, and a digital surgery platform.

A pivotal element of this transformation is the GenesisX RMN System. Unlike its predecessors, GenesisX is designed for rapid, weekend installation without the need for structural modifications or extensive magnetic shielding built into the lab walls. This is achieved through smaller magnets and magnetic shielding integrated directly into the robotic base, along with streamlined electronics and cabling. This innovation is intended to dramatically shorten sales cycles and enable a transition from a capital-intensive construction model to a more flexible placement model, significantly enhancing accessibility for hospitals. GenesisX received CE Mark in Europe and a 510(k) submission has been made to the US FDA, with regulatory clearance viewed as realistic in the summer of 2025. Initial soft launch efforts, including live demonstrations at major EP conferences, have begun, with the first commercial installation expected in Europe this summer.

Complementing the GenesisX system is the development of a proprietary catheter portfolio. The Stereotaxis MAGiC ablation catheter, which obtained CE marking in Europe in Q1 2025 and is seeking US FDA approval in the second half of 2025, is a critical component. Designed with enhancements for improved stability, navigation, and information feedback compared to the legacy third-party catheter, MAGiC is expected to significantly improve the clinical experience. From a commercial standpoint, it is projected to substantially increase disposable revenue per procedure, addressing the historical "razor blade" deficiency. Initial commercial sales of MAGiC have begun at approximately 20% of European hospital customers who have completed administrative processes, and management expects European MAGiC revenue to reach a $1 million quarterly run rate by the end of 2025.

The acquisition of Access Point Technologies (APT) in July 2024 further accelerated the catheter strategy, bringing in-house development and manufacturing expertise and a portfolio of differentiated diagnostic EP catheters (Map-iT). This integration is already contributing to recurring revenue growth, with Map-iT sales exceeding $1 million in Q1 2025 and US sales growing 30% sequentially. Beyond Map-iT and MAGiC, Stereotaxis is advancing other proprietary catheters, including the MAGiC Sweep (robotic high-density mapping catheter) and EMAGIN (vascular guide catheter), both submitted for US/EU regulatory approval in Q1 2025 with expected clearance in Q3 2025. The company is also pursuing multiple PFA (Pulsed Field Ablation) initiatives, including one potentially commercially available in Europe in 2025, and developing a robotically-steered vascular guidewire expected to be completed by year-end 2025. The introduction of MAGiC and MAGiC Sweep alone is expected to increase disposable revenue per procedure approximately five-fold.

Recent financial performance reflects the early impact of this strategic shift. For the three months ended March 31, 2025, total revenue grew 9% year-over-year to $7.5 million. This growth was primarily driven by a 29.1% increase in recurring revenue to $5.5 million, largely attributable to the inclusion of post-acquisition Map-iT catheter sales and initial MAGiC sales in Europe. System revenue, however, decreased by 24.8% to $2.0 million, reflecting the inherent lumpiness of capital sales and volume changes in system-related products. Gross margin decreased to 54% overall, with recurring revenue gross margin at 68% impacted temporarily by acquisition-related accounting adjustments for acquired inventory valuation, which is expected to normalize by Q3 2025. System gross margin remained low at 15%, influenced by fixed overhead allocation over low production volumes. Operating expenses increased by 14.7% to $10.0 million, primarily due to acquisition-related costs like contingent consideration revaluation and intangible asset amortization, as well as higher administrative and professional service fees. This resulted in a net loss of $5.8 million for the quarter.

Despite the continued net losses and a decrease in cash and cash equivalents to $10.6 million at March 31, 2025, management maintains that existing cash is sufficient for the next twelve months, supported by expectations for reduced cash use in 2025 compared to 2024. This is predicated on growing recurring revenue and stable adjusted operating expenses, with future commercial investments funded by incremental profit from new product launches.

Looking ahead, management has reiterated guidance for double-digit revenue growth in the full year 2025. System revenue is expected to fluctuate quarterly between $2 million and $3 million, with this guidance conservatively assuming only modest GenesisX contributions in Europe and no system revenue from the US or China due to pending regulatory clearances and macroeconomic uncertainty. Recurring revenue is projected to scale throughout the year, reaching an expected $7 million in the fourth quarter of 2025, driven by the ramp-up of proprietary catheter sales, particularly MAGiC in Europe.

The competitive landscape in interventional medicine is dominated by large, well-established players like Medtronic, Abbott Laboratories, and Boston Scientific, who offer broad portfolios of devices and systems, including some robotic or advanced navigation tools. Intuitive Surgical (ISRG) is a leader in surgical robotics, though not directly in Stereotaxis' primary endovascular space. These competitors benefit from significant scale, extensive distribution networks, and robust financial resources, enabling them to invest heavily in R&D and potentially exert pricing pressure. Stereotaxis' competitive advantage lies in its unique RMN technology, offering precision and safety benefits, particularly in complex cases. The strategic transformation, centered on GenesisX and the proprietary catheter ecosystem, is designed to directly counter competitive disadvantages by improving accessibility, building a strong recurring revenue model, and expanding into new, large endovascular markets where the technology's navigation capabilities can add significant value. While precise market share figures for all niche segments are challenging to ascertain, the focus on differentiated technology and addressing historical limitations positions Stereotaxis to potentially capture share in its target markets.

However, significant risks remain. Macroeconomic and geopolitical factors, including supply chain disruptions, inflation, and tariffs, could impact operations and demand. Hospital customers face their own financial and staffing pressures, potentially delaying capital purchases and impacting procedure volumes. The complexity of integrating the APT business and scaling catheter manufacturing presents operational challenges. Regulatory approval timelines, while progressing, are inherently uncertain. The company's history of significant losses and the need for future funding, although not anticipated in the next 12 months based on current projections, remain a risk if growth does not materialize as expected or if market conditions deteriorate.

Conclusion

Stereotaxis is at a critical juncture, actively executing a strategic transformation aimed at overcoming historical limitations and unlocking significant growth potential. The development and initial commercialization of the GenesisX system and a proprietary catheter portfolio, catalyzed by the APT acquisition, represent a fundamental shift in the company's business model and market approach. Early financial indicators in Q1 2025, particularly the strong growth in recurring revenue driven by new proprietary catheters, provide initial validation of this strategy. While the path forward involves navigating macroeconomic uncertainties, operational complexities, and intense competition from larger players, the successful realization of upcoming regulatory milestones and the ramp-up of new product launches are expected to drive double-digit revenue growth in 2025 and set the stage for potentially more substantial growth in 2026. For investors, the thesis hinges on Stereotaxis' ability to translate its technological differentiation and expanded product ecosystem into increased adoption, a more favorable financial profile, and a stronger competitive position within the evolving landscape of interventional robotics.
```